590355 Disclosed are N-[1,3,4-oxadiazol-2-yl]-4-quinolinecarboxamide derivatives as represented by the general formula (I), wherein R4a represents a hydrogen atom W represents a single bond or an unsubstituted alkylene group X represents an oxygen atom, a sulfur atom, or NR34 and wherein the remaining substituents are as defined herein. Representative compounds include N-[5-(2-furyl)-1,3,4-oxadiazol-2-yl]-2-phenyl-4-quinolinecarboxamide, 2-phenyl-N-(5-phenyl-1,3,4-oxadiazol-2-yl)-4-quinolinecarboxamide, N-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-phenyl-4-quinolinecarboxamide, 2-phenyl-N-[5-(3-pyridyl)-1,3,4-oxadiazol-2-yl]-4-quinolinecarboxamide and N-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-4-quinolinecarboxamide. Further disclosed is a pharmaceutical composition, containing as an active ingredient, a quinolinecarboxamide derivative as defined above, or a pharmacologically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent excipient and/or adjuvant for the treatment of cancer.
